AVXS AveXis, Inc.

77.00
+0  (0%)
Previous Close 76.93
Open 77.41
Price To book 8.66
Market Cap 2.14B
Shares 27,739,000
Volume 237,947
Short Ratio 15.93
Av. Daily Volume 400,450

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Initiate pivotal trial in 2Q 2017 pending a successful outcome of its FDA Type B CMC meeting.
AVXS-101
Spinal muscular atrophy (SMA) Type 1

Latest News

  1. AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Meeting of the American Academy of Neurology
  2. Which Biotechs Are Buyable As Sector Recovers In 2017?
  3. Cytokinetics SMA Drug Did Well in Early Study
  4. Billionaires' Best Healthcare Stock Picks of 2017 (So Far)
  5. AveXis, Inc. (AVXS) Looks Good: Stock Moves 15.4% Higher
  6. AveXis Inc Stock Is Spiking Again Today -- Here's Why
  7. AveXis, Esperion and Amgen Among Biotech Movers
  8. AveXis Reports Positive Data for SMA Gene Therapy
  9. AveXis Offers Easily The Best Treatment Option For SMA Type-1 Patients
  10. Edited Transcript of AVXS earnings conference call or presentation 16-Mar-17 8:30pm GMT
  11. Futures Steady: 2 'A' Stocks Set To Soar, 1 Mule Ready To Kick
  12. After-hours buzz: ADBE, AVXS, GOOS & more
  13. AveXis reports 4Q loss
  14. AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results
  15. 5 Earnings Short-Squeeze Plays: Tiffany, Athene and More
  16. Blog Coverage Heat Biologics Acquires Controlling Stake in Immuno-Oncology Company Pelican Therapeutics
  17. AveXis to Report Topline Phase 1 Trial Results in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results on March 16, 2017
  18. Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High
  19. AveXis to Present Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at AAN Annual Meeting
  20. 3 Stocks Setting Up for Major Breakouts